View Older Stories View More Recent Stories

Oct 19, 2022 06:01AM Jazz (JAZZ) and Zymeworks (ZYME) Enter License Agreement to Develop and Commercialize Zanidatamab
Oct 19, 2022 06:00AM Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Oct 18, 2022 08:30AM Zymeworks to Host Third Quarter Results Conference Call
Oct 13, 2022 07:00AM Zymeworks Completes Plan to Become Delaware Corporation
Oct 7, 2022 04:15PM Zymeworks Announces Results of Special Meeting
Oct 4, 2022 08:30AM Zymeworks Reminds Shareholders to Vote FOR its Redomicile
Oct 3, 2022 08:30AM Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
Sep 26, 2022 04:15PM Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
Sep 16, 2022 08:31AM Zymeworks (ZYME) Announces Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
Sep 16, 2022 08:30AM Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
Sep 12, 2022 04:16PM Zymeworks (ZYME) eports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at ESMO
Sep 12, 2022 04:15PM Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
Sep 8, 2022 04:15PM Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
Sep 4, 2022 06:05PM Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
Aug 4, 2022 04:15PM Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Aug 1, 2022 08:30AM Zymeworks Announces Participation in Upcoming Investor Conferences
Jul 25, 2022 08:30AM Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
Jul 22, 2022 08:30AM Zymeworks Reports Inducement Grant to New Chief Scientific Officer
Jul 21, 2022 08:30AM Zymeworks to Host Second Quarter Results Conference Call
Jul 15, 2022 08:00AM Zymeworks Announces Plan to Become a Delaware Corporation
Jun 27, 2022 08:34AM Zymeworks (ZYME) Appoints Paul Moore as Chief Scientific Officer
Jun 27, 2022 08:30AM Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
Jun 10, 2022 09:15AM Zymeworks (ZYME) Adopts Limited-Duration Shareholder Rights Plan, Enables Shareholders to Realize Full Value of Company
Jun 10, 2022 09:15AM Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
Jun 7, 2022 08:00AM Cytovia Therapeutics Appoints Luca Scavo as Chief Financial Officer and James Priour as Chief Product Officer
May 27, 2022 05:30AM Zymeworks Announces Participation in Upcoming Investor Conference
May 26, 2022 05:08PM Zymeworks (ZYME) Announces Positive Zanidatamab Antitumor Activity at ASCO
May 26, 2022 05:00PM Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
May 20, 2022 09:15AM Zymeworks’ (ZYME) Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
May 20, 2022 09:15AM Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
May 4, 2022 04:15PM Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 2, 2022 08:30AM Zymeworks Announces Participation in Upcoming Investor Conferences
Apr 29, 2022 05:52AM Zymeworks (ZYME) Confirms $10.50/sh Acquisition Offer from All Blue Falcons
Apr 28, 2022 09:00PM Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
Apr 28, 2022 08:30AM Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
Apr 27, 2022 04:15PM Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 19, 2022 04:15PM Zymeworks to Host First Quarter 2022 Results Conference Call
Apr 5, 2022 04:02PM Atreca (BCEL) Announces Expansion of Preclinical Pipeline
Apr 5, 2022 04:01PM Atreca Announces Expansion of Preclinical Pipeline
Apr 5, 2022 04:01PM Atreca Announces Expansion of Preclinical Pipeline
Apr 1, 2022 08:30AM Zymeworks Announces Participation in Upcoming Investor Conferences
Mar 3, 2022 08:30AM Zymeworks Announces Participation in Upcoming Investor Conferences
Feb 24, 2022 04:15PM Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
Feb 8, 2022 04:15PM Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
Feb 3, 2022 04:15PM Zymeworks Announces Participation in Upcoming Investor Conferences
Jan 19, 2022 04:18PM Zymeworks (ZYME) Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
Jan 19, 2022 04:15PM Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
Jan 15, 2022 08:30AM Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
Jan 6, 2022 08:30AM Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
Jan 5, 2022 04:30PM Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
View More Recent Stories View Older Stories